Company Overview
About bit.bio
bit.bio is a synthetic biology company founded in 2016 as a spinout from the Luscher laboratory at the University of Cambridge, headquartered in Cambridge, United Kingdom. The company's core technology platform, opti-ox (optimized overexpression), enables the precise and highly reproducible reprogramming of human induced pluripotent stem cells (iPSCs) into virtually any human cell type — neurons, cardiomyocytes, hepatocytes, immune cells, and more — with a consistency and scalability that has historically been impossible to achieve with conventional differentiation protocols. This precision is achieved by engineering the transcription factor expression cassette into a defined genomic safe harbor site, ensuring every cell in a batch receives the same reprogramming instruction.
Business Model & Competitive Advantage
bit.bio raised £71M in a Series B funding round, with investors including Foresite Capital, Agilent Technologies, DCVC, and Atomico. The company's primary commercial offering is high-quality human cell products — sold under the ioCell brand — to pharmaceutical and biotech companies for drug discovery, disease modeling, and toxicology testing. By providing standardized, well-characterized human cells rather than animal cells or inconsistently derived human primary cells, bit.bio enables more predictive preclinical research and reduces the translatability gap between lab findings and clinical outcomes. This addresses one of the most persistent failure points in drug development: results that work in animal or inconsistent cell models but fail in human trials.
Competitive Landscape 2025–2026
bit.bio is also developing capabilities in cell therapy manufacturing — where the same opti-ox precision that produces research-grade cells could enable the manufacturing of allogeneic (off-the-shelf) cell therapies at the scale and consistency required for commercial pharmaceutical production. This positions bit.bio at the intersection of life science tools, drug discovery, and regenerative medicine manufacturing. The company competes with cell biology suppliers such as Thermo Fisher Scientific, Lonza, and ATCC, as well as specialist iPSC companies such as Fujifilm CDI and BlueRock Therapeutics.
Key Differentiators
Emerging Innovator
bit.bio is an emerging player bringing innovative solutions to the Life Sciences & BioTech market.
Frequently Asked Questions
Similar Brands
Pliant Therapeutics
Pliant Therapeutics develops small molecule integrin inhibitors targeting the pathological tissue scarring (fibrosis) that drives diseases including idiopathic pulmonary fibrosis (IPF), primary sclero
Neuralink
Neuralink is a neurotechnology company founded in 2016 by Elon Musk and a team of neuroscientists and engineers, developing implantable brain-computer interface devices that enable individuals with pa
BioNTech
BioNTech SE was founded in 2008 in Mainz, Germany by Ugur Sahin, Ozlem Tureci, and Christoph Huber with a mission to harness the immune system for individualized cancer treatment. The company pioneere
Illumina
Illumina was founded in 1998 in San Diego and has grown into the undisputed leader in next-generation sequencing (NGS), with approximately 80% global market share across research and clinical applicat
Genentech
Genentech was founded in 1976 in South San Francisco by Herbert Boyer and Robert Swanson, becoming the first company to produce human insulin using recombinant DNA technology and essentially launching
Regeneron
Regeneron Pharmaceuticals was founded in 1988 in Tarrytown, New York by Leonard Schleifer and George Yancopoulos. The company built its reputation on the Velocimmune platform—a proprietary humanized m
Compare bit.bio with Competitors
Side-by-side AI visibility scores, platform breakdown, and market position.
Claim This Profile
Are you from bit.bio? Claim your profile to see full AI mention excerpts, get weekly visibility change alerts, and optimize how AI systems describe your brand.
Claim bit.bio Profile →Track AI Visibility in Real Time
Monitor how ChatGPT, Gemini, Perplexity, and Claude mention bit.bio vs competitors. Get alerts when AI recommendations shift.
Start Free Tracking →